Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant ...

For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the ...

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant ...

An analysis of phase 3 trials found tamoxifen significantly reduced 15-year ipsilateral breast recurrence in patients with ...

This conclusion comes from the phase 3 study EA4151, conducted by the ECOG-ACRIN Cancer Research Group. The trial, which ...

A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission ...

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL) in remission following ...

The test leverages the company’s immune medicine platform to quantify specific DNA sequences found in malignant cells.

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant ...

Autologous stem cell transplant plus Rituxan did not improve survival outcomes in certain patients with mantle cell lymphoma compared with Rituxan alone.

The 66th American Society of Hematology Annual Meeting & Exposition will take place December 7-10, 2024, in San Diego, ...